Germany · Delayed Price · Currency is EUR AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of EUR 298.66 billion. The enterprise value is 354.86 billion.
| Market Cap | 298.66B |
| Enterprise Value | 354.86B |
Important Dates
The last earnings date was Friday, July 25, 2025.
| Earnings Date | Jul 25, 2025 |
| Ex-Dividend Date | Jul 15, 2025 |
Share Statistics
| Current Share Class | 1.77B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 94.21 and the forward PE ratio is 14.88.
| PE Ratio | 94.21 |
| Forward PE | 14.88 |
| PS Ratio | 6.01 |
| PB Ratio | 239.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 111.94 |
| EV / Sales | 7.02 |
| EV / EBITDA | 14.58 |
| EV / EBIT | 21.01 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 47.90 |
| Debt / EBITDA | 2.44 |
| Debt / FCF | n/a |
| Interest Coverage | 6.38 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 16.86% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 903,023 |
| Profits Per Employee | 57,639 |
| Employee Count | 55,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -630.96M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.66% in the last 52 weeks. The beta is 0.48, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -2.66% |
| 50-Day Moving Average | 163.25 |
| 200-Day Moving Average | 172.14 |
| Relative Strength Index (RSI) | 59.50 |
| Average Volume (20 Days) | 584 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AbbVie had revenue of EUR 49.67 billion and earned 3.17 billion in profits. Earnings per share was 1.79.
| Revenue | 49.67B |
| Gross Profit | 35.41B |
| Operating Income | 17.14B |
| Pretax Income | 2.58B |
| Net Income | 3.17B |
| EBITDA | 24.18B |
| EBIT | 17.14B |
| Earnings Per Share (EPS) | 1.79 |
Balance Sheet
The company has 4.41 billion in cash and 59.63 billion in debt, giving a net cash position of -55.22 billion.
| Cash & Cash Equivalents | 4.41B |
| Total Debt | 59.63B |
| Net Cash | -55.22B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.24B |
| Book Value Per Share | 0.68 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 71.30%, with operating and profit margins of 34.52% and 6.45%.
| Gross Margin | 71.30% |
| Operating Margin | 34.52% |
| Pretax Margin | 5.19% |
| Profit Margin | 6.45% |
| EBITDA Margin | 48.68% |
| EBIT Margin | 34.52% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 5.86, which amounts to a dividend yield of 3.48%.
| Dividend Per Share | 5.86 |
| Dividend Yield | 3.48% |
| Dividend Growth (YoY) | 3.22% |
| Years of Dividend Growth | 6 |
| Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | 3.45% |
| Earnings Yield | 1.06% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |